Norepinephrine Transporter antibody

Background of Norepinephrine Transporter antibody

Many physiological, endocrine and behavioral functions are determined and regulated by monoamine sigling. Many brain disorders such as depression, drug abuse, schizophrenia, attention deficit hyperactivity disorder (ADHD) are caused by the malfunction of monoaminergic transmission. The intensity of monoaminergic sigling is determined by the availability of the monoamine, which is in turn determined in part by its uptake from the extracellular milieu via monoamine transporters. These transporters include DAT, SERT, and NET, responsible for uptaking dopamine, serotonin and noradreline respectively, and recycling them back for release. While the activity of each transporter is faithful to its neurotransmitter, NET has been shown to clear dopamine in DAT deprived or low DAT regions such as the brain cortex. DAT, SERT and NET are members of the +/Cl dependent membrane transporter family which also includes other members. These transporters consist of 12 transmembrane domains and intracellular N- and C-termini. NET also has a significant extracellular loop between transmembrane regions three and four, which contains various glycosylation sites. Like its counterparts, NETâ??s intracellular N- and C-termil domains are also subject to phosphorylation and protein-protein interactions important for modulating its activity and localization. In addition altertive splicing has also been shown to regulate NETâ??s expression and function. NET is specifically expressed on noradreline nerve termils, and is also expressed in the periphery, such as adrel glands and placenta. NET malfunction is largely associated with attention and mood, as well as various cardiovascular disorders. NET is also a target for psychostimulants such as cocaine and amphetamines which disrupt its function, thereby causing an increase of noradreline in syptic clefts.